ADXS
$0.38
Advaxis
ADXS
Earnings Whisper ®
N/A
4th Quarter October 2019
Consensus:  ($1.37)
Revenue:  N/A
Monday
Dec 9
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ADXS reports earnings?
Beat
Meet
Miss

Where is ADXS's stock price going from here?
Up
Flat
Down
Stock chart of ADXS
Analysts
Summary of analysts' recommendations for ADXS
Score
Grade
Pivots
Resistance
$0.43
$0.41
$0.40

$0.37

Support
$0.36
$0.33
$0.32
Tweet
Growth
Description
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
Peers
BiogenGilead SciencesAmgenBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsRepligenNovavax